// App-Quantinova.ai

258 : Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial

Researchers

Presenter

  • Hasan Tahir

Principal Investigators

  • Philip J Mease

  • Arthur Kavanaugh

  • Andreas Reimold

  • Jrgen Rech

  • Stephen Hall

  • Piet Geusens

  • Pascale Pellet

  • Eumorphia Maria Delicha

  • Luminita Pricop

  • Shephard Mpofu

Medical Centers

  • Rheumatology, Barts Health NHS Trust, London, UNITED KINGDOM

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • San Diego School of Medicine, University of California, La Jolla, CA

  • Dallas Veterans Affairs Medical Center and University of Texas Southwestern Medical Center, Dallas, TX

  • Department of Internal Medicine Rheumatology and Immunology, Universitatsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nurnberg FAU, Erlangen, Germany

  • Rheumatology, Emeritus Research, Camberwell, AUSTRALIA

  • Rheumatology, University of Hasselt, Hasselt, BELGIUM

  • Immunology & Dermatology Franchise, Novartis Pharma AG, Basel, SWITZERLAND

  • Biostatistics, Novartis Pharma AG, Basel, SWITZERLAND

  • Immunology and Dermatology Franchise, Novartis Pharma AG, East Hanover, NJ

Locations

  • United Kingdom

  • United States

  • Germany

  • Australia

  • Belgium

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Dose Escalation

Phase

  • III

Study Id's

  • NCT01392326

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved